PEDIATRIC AIDS CLINICAL TRIALS GROUP

Project: Research project

Description

The objective of this proposal is to develop a comprehensive
chemotherapy program to assess therapies directed against HIV
infection in children. Our long term goals are to provide
treatment for all children and to develop strategies for prevention
of disease in children. The specific aims of this proposal are:
1.) to develop a program that will provide for efficient and
effective assessment of the efficacy and toxicity of both antiviral
drugs and other agents directed against HIV and its complications:
2.) to provide expertise and assistance In protocol development
for evaluation of new agents on a timely basis; 3.) to develop a
registry for rapid patient identification and efficient accrual
into chemotherapy trials; and 4.) to conduct trials in all phases
of study from inception to Phase 3 protocols. The number of cases
of AIDS in children has continued to increase, with Florida ranking
third nationally in the number of pediatric AIDS cases reported.
The University of Miami/Jackson Memorial Hospital Medical Center
has studied over 200 patients with pediatric AIDS and presently
follows 120 HIV-infected children. An integrated pediatric program
with a strong emphasis on clinical and basic science research in
the area of pediatric HIV infection has already been developed and
is in place to support the proposed program. A major goal of the
clinical is the prevention of HIV-infection and the provision of
treatment for children. Prospective studies of infants born to HIV
seropositive are currently in progress and provide a readily
available population of patients for early identification of
infected infants and potential study recruitment. Outpatient and
inpatient facilities have been developed for the care and followup
of these children. Laboratory facilities for HIV serology and
virology, immunologic determinations related to AIDS and
pharmacologic assays are readily available at our center and are
headed by personnel with prior experience in both adult and
pediatric HIV drug treatment protocols. Our group has experience
in designing and carrying both Phase 1 and Phase 2 multicenter
collaborative clinical trials of AZT. This proposal will bring a
new dimension to the treatment of pediatric AIDS at our center and
adds perspective to the ongoing research studies.
StatusFinished
Effective start/end date9/30/882/28/07

Funding

  • National Institutes of Health: $273,119.00
  • National Institutes of Health
  • National Institutes of Health: $1,336,540.00
  • National Institutes of Health
  • National Institutes of Health: $1,354,077.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $686,001.00
  • National Institutes of Health: $1,545,369.00
  • National Institutes of Health
  • National Institutes of Health: $1,923,160.00
  • National Institutes of Health: $999,382.00
  • National Institutes of Health: $1,981,587.00
  • National Institutes of Health: $391,546.00
  • National Institutes of Health: $1,133,574.00
  • National Institutes of Health: $1,461,812.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $1,167,578.00
  • National Institutes of Health

Fingerprint

Clinical Trials
Pediatrics
Acquired Immunodeficiency Syndrome
HIV Infections
HIV
Virology
Obstetrics
Research
Allergy and Immunology
Opportunistic Infections
HIV-1
Infectious Disease Medicine
Dominican Republic
Adolescent Medicine
Zambia
Medical Informatics
Population
Clinical Protocols
Pregnant Women
Therapeutics

ASJC

  • Medicine(all)
  • Immunology and Microbiology(all)